Investigation on the effectiveness of a new hoof care product to sustainably reduce and prevent Digital Dermatitis in dairy cow herds.

J Dairy Sci

Hoof Health Associates (Praxisgemeinschaft für Klauengesundheit) Dres. med. vet. Fiedler, Grimm & Kröger, Munich, Germany.

Published: October 2024

AI Article Synopsis

  • - The study examines the effectiveness of a new hoof care product containing iron, zinc, and aluminum salts for reducing Digital Dermatitis (DD) in dairy cows, compared to traditional treatments like formalin and copper sulfate, which have questionable efficacy and may cause irritation and environmental harm.
  • - Over a year-long clinical trial involving 132 cows, the treatment group received bi-weekly applications of the product on one hind foot, while the control group only had the other hind foot washed, with monthly assessments of DD severity.
  • - Results indicated the treatment group had significantly less disease severity, with the control group showing a 4 times higher likelihood of having lesions and a nearly 6 times higher chance of active lesions compared to the treatment group.

Article Abstract

The regular application of hoof care and cleaning products is an important part of protocols designed to reduce burden of disease caused by the ubiquitous and multifactorial hoof disease Digital Dermatitis (DD) in dairy cows. Commonly used hoof care products such as formalin or copper sulfate applied through foot baths or by spraying hindfeet are often irritant to the skin as well as harmful to the environment or human health while scientifically proven evidence of their efficacy is scarce. Thus, in a clinical controlled trial, we investigated if the use of a hoof care product based on a mix of iron complex salts, zinc salts and aluminum designed to reduce bacterial load on the skin and to support the natural skin barrier, was able to sustainably reduce disease severity and prevent new cases in 132 cows in 2 dairy herds (n = 72, n = 60) in Germany. From Dec 2021 to Dec 2022 only one predefined hind foot of every cow was washed and sprayed with the product twice a week (treatment group), the other hind foot was only washed (control group). Heifers joining the herd were sprayed for at least 4 weeks beforehand according to the same treatment and control regimen. During the trial, hooves were scored for DD lesions on a monthly basis using a disease severity score (A): from 0 = no lesion, up to 60 = ulcerative lesion ≥2.5 cm and categorically with 3 categories (B): 'none', 'non-active' and 'active'. Results A: Mean area under the curve of the numerical score that summarizes development over time was substantially and statistically significantly smaller in the treatment group. Results B: Two-step regression analysis for the outcome category at evaluation day (with exclusion of the first baseline evaluation) showed that during the trial, compared with the treatment group, odds of having a lesion rather than none was 4 times higher in the control group and the odds of having an active lesion compared with an inactive one were almost 6 times higher in the control group. Additionally, spraying had a statistically significant preventive effect for the feet of heifers (n = 17) introduced to the herd during the trial on farm 1: Only one active lesion occurred in the treatment group with numerous active lesions observed in the control group and mean area under the curve of the numerical score over time was statistically significantly lower in the treatment group, too. No active lesions occurred in heifers of farm 2 (n = 12) in either of the study groups. The iron, zinc and aluminum-based product effectively reduced disease prevalence and disease severity during the one-year study period in the examined dairy herds and data from heifers suggest that the application of the product to heifers 4 weeks before entering a herd with controlled DD management measures has high potential for prevention of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.3168/jds.2024-25134DOI Listing

Publication Analysis

Top Keywords

treatment group
20
hoof care
16
control group
16
disease severity
12
group
9
care product
8
sustainably reduce
8
digital dermatitis
8
dermatitis dairy
8
designed reduce
8

Similar Publications

Combination therapy, which involves using multiple therapeutic modalities simultaneously or sequentially, has become a cornerstone of modern cancer treatment. Graphene-based nanomaterials (GBNs) have emerged as versatile platforms for drug delivery, gene therapy, and photothermal therapy. These materials enable a synergistic approach, improving the efficacy of treatments while reducing side effects.

View Article and Find Full Text PDF

Transcriptomic Profiles in Nasal Epithelium and Asthma Endotypes in Youth.

JAMA

January 2025

Division of Pediatric Pulmonary Medicine, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania.

Importance: T helper 2 (T2) cells and T helper 17 (T17) cells are CD4+ T cell subtypes involved in asthma. Characterizing asthma endotypes based on these cell types in diverse groups is important for developing effective therapies for youths with asthma.

Objective: To identify asthma endotypes in school-aged youths aged 6 to 20 years by examining the distribution and characteristics of transcriptomic profiles in nasal epithelium.

View Article and Find Full Text PDF

Importance: Mania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.

Objective: To replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity during reward expectancy (RE) and mania/hypomania risk, to explore the effect of MDD history on this association, and to compare RE-related left vlPFC activity in individuals with and at risk of BD.

View Article and Find Full Text PDF

Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).

Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!